Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis

Journal of Neuroinflammation, Journal Year: 2023, Volume and Issue: 20(1)

Published: Nov. 27, 2023

As one of most common and severe mental disorders, major depressive disorder (MDD) significantly increases the risks premature death other medical conditions for patients. Neuroinflammation is abnormal immune response in brain, its correlation with MDD receiving increasing attention. has been reported to be involved through distinct neurobiological mechanisms, among which dysregulation neurogenesis dentate gyrus (DG) hippocampus (HPC) The DG two niches adult mammalian neurotrophic factors are fundamental regulators this process. cell types mediating neuroinflammation include microglia, astrocytes, oligodendrocytes, meningeal leukocytes, peripheral cells selectively penetrate blood-brain barrier infiltrate into inflammatory regions. This review summarizes functions affected by during progression corresponding influences on memory patients model animals.

Language: Английский

---

BDNF Unveiled: Exploring Its Role in Major Depression Disorder Serotonergic Imbalance and Associated Stress Conditions

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(8), P. 2081 - 2081

Published: Aug. 3, 2023

Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays significant role in the survival and development of neurons, being involved several diseases such as Alzheimer’s disease major depression disorder. The association between BDNF depressive disorder subject extensive research. Indeed, numerous studies indicate decreased levels are linked to an increased occurrence symptoms, neuronal loss, cortical atrophy. Moreover, it has been observed antidepressive therapy can help restore levels. In this review, we will focus on serotonergic imbalance associated stress conditions, particularly hypothalamic–pituitary–adrenal (HPA) axis dysregulation oxidative stress. All these features highly connected signaling pathways context disease, exploring topic aim advance our understanding disorder, improve diagnostic treatment approaches, potentially identify new therapeutic targets alleviate heavy burden society.

Language: Английский

---

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Journal of Cellular and Molecular Medicine, Journal Year: 2024, Volume and Issue: 28(10)

Published: May 1, 2024

Parkinson's disease (PD) is a neurodegenerative disorder of the brain and manifested by motor non-motor symptoms because degenerative changes in dopaminergic neurons substantia nigra. PD neuropathology associated with mitochondrial dysfunction, oxidative damage apoptosis. Thus, modulation apoptosis growth factors could be novel boulevard management PD. Brain-derived neurotrophic factor (BDNF) its receptor tropomyosin kinase type B (TrkB) are chiefly involved neuropathology. BDNF promotes survival nigra enhances functional activity striatal neurons. Deficiency TrkB triggers degeneration accumulation α-Syn As well, BDNF/TrkB signalling reduced early phase Targeting specific activators may attenuate this review aimed to discuss potential role against In conclusion, decreased linked severity long-term complications. Activation

Language: Английский

---

Effects of pain in lumbosacral stenosis and lifestyle-related factors on brain-derived neurotrophic factor expression profiles

Molecular Pain, Journal Year: 2025, Volume and Issue: 21

Published: Jan. 1, 2025

This study investigated the role of brain-derived neurotrophic factor (BDNF) in patients with degenerative lumbar stenosis, focusing on its expression and correlation pain intensity. The examined 96 stenosis 85 control participants. BDNF levels yellow ligamentum flavum were measured using reverse transcription quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), western blot analysis. results showed significantly higher at both messenger ribonucleic acid (mRNA; fold change = +1.35 ± 0.23; p < 0.05) protein (28.98 6.40 pg/mg) compared to controls (4.56 1.98 pg/mg; 0.05). Furthermore, correlated positively intensity reported by patients, observed those experiencing more severe pain. also explored influence lifestyle factors, such as smoking alcohol consumption, related diseases, diabetes, expression. Smoking, use, diabetes associated elevated ( These findings suggest that could serve a biomarker for severity level, although this was not consistently mRNA level; highlights potential BDNF-targeted therapies managing Future research should involve larger longitudinal studies validate these explore therapeutic interventions. underscores importance considering molecular factors treatment aiming improve patient outcomes through comprehensive, targeted approaches.

Language: Английский

---

BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?

Molecules, Journal Year: 2022, Volume and Issue: 27(24), P. 8823 - 8823

Published: Dec. 12, 2022

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder and common cause of dementia in elderly. The complexity AD has hindered development either a cure or disease-modifying therapy to halt progression. Numerous hypotheses were presented order explain mechanisms underlying pathogenesis AD. Introduced 1992, “Amyloid Cascade Hypothesis” had huge impact on field inspired rise various drug candidates, especially amyloid-beta (Aβ)-directed drugs; including beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. Adopted by number pharmaceutical companies, BACE1 inhibitors gained momentum past decade with promising results from experimental early clinical-phase studies. Nevertheless, nearly all failed later phases clinical trials, due safety and/or efficacy issues, others discontinued favor second-generation small-molecule candidates. This paper aims provide comprehensive review ever reach we discuss challenges different perspectives whether are be reconsidered revitalized future.

Language: Английский

---

New insights into the role of berberine against 3-nitropropionic acid-induced striatal neurotoxicity: Possible role of BDNF–TrkB–PI3K/Akt and NF-κB signaling

Food and Chemical Toxicology, Journal Year: 2023, Volume and Issue: 175, P. 113721 - 113721

Published: March 11, 2023

Language: Английский

---

The Compelling Role of Brain‐Derived Neurotrophic Factor Signaling in Multiple Sclerosis: Role of BDNF Activators

CNS Neuroscience & Therapeutics, Journal Year: 2024, Volume and Issue: 30(12)

Published: Dec. 1, 2024

Brain-derived neurotrophic factor (BDNF) is a neurotrophin, acting as signal and neuromodulator in the central nervous system (CNS). BDNF synthesized from its precursor proBDNF within CNS peripheral tissues. Through activation of NTRK2/TRKB (neurotrophic receptor tyrosine kinase 2), promotes neuronal survival, synaptic plasticity, growth, whereas it inhibits microglial release pro-inflammatory cytokines. dysregulated different neurodegenerative diseases depressions. However, there major controversy concerning levels stages multiple sclerosis (MS). Therefore, this review discusses potential role signaling MS, how modulators affect pathogenesis outcomes disease.

Language: Английский

---

Methamphetamine inhibits huntingtin-associated protein 1-mediated tyrosine receptor kinase B endocytosis resulting the neuroprotective dysfunction of brain-derived neurotrophic factor

Toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 154047 - 154047

Published: Jan. 1, 2025

Language: Английский

---

Research Progress on MECT Combined with Second-Generation Antipsychotic Drugs in the Treatment of Schizophrenia

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(01), P. 871 - 877

Published: Jan. 1, 2025

Language: Английский

---

Hippocampal overexpression of tissue-type plasminogen activator “tPA” attenuates social defeat-induced depression and ethanol related behavior in mice

Alcohol, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---